Sandoz Will Wait A Decade On Amantadine
Patent-Litigation Settlement Permits 2030 Launch
Sandoz will be able to launch a generic of Adamas’ amantadine-based Gocovri brand in the US from March 2030. But a patent-litigation settlement permits an earlier entry if sales of the dyskinesia brand decline.
